Gateway 2012: Rommelag - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2012: Rommelag



Your online Gateway to Rommelag in 2012

27905 Meadow Dr., Suite 9
PO Box 2530
Evergreen, CO  80437
303-674-8333
303-670-2666
www.rommelag.com

Don't miss Rommelag at Interphex 2012, May 1–3, Javits Center, New York, N.Y.

About Rommelag

Rommelag custom designs and builds blow/fill/seal machines for advanced aseptic liquid packaging. We serve the pharmaceutical, healthcare, cosmetic and chemical industries. Applications start at 0.1 mL. Packages such as ampoules, vials, bags, bottles, bellows, are all formed, filled, and sealed in one cycle on one machine. This year we are once again a featured company in the Advanced Aseptic Technologies Tour, register at www.interphex.com/Register.

Visit our Booth: # 2617, contact mail@rommelag.com to set an appointment time during the show.

Rommelag® representatives will be at Interphex 2012 to talk with your organization about the advantages of the Blow-Fill-Seal process for all your Advanced Aseptic liquid packaging needs. The Blow-Fill-Seal process is a fully automated Advance Aseptic system for producing Large Volume Parenteral (LVP) and Small Volume Parenteral (SVP) products. Pharmaceutical companies worldwide are switching from glass ampoules and bottles to the durable, lightweight, plastic bottles formed with the Blow–Fill–Seal process. rommelag® has been providing the industry with superior quality machines and support for over 40 years.

 

 

 



ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
8%
All of the above.
42%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here